CAI Share Price Performance
US$28.24
0.24 (0.86%)
37.2% undervalued intrinsic discount
US$45.00
Fair Value
Price US$28.24
AnalystHighTarget US$45.00
Fair ValueUS$45.00
Share Pricen/a
Caris Life Sciences, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
CAI Community Narratives
AN
Fair Value US$45 37.2% undervalued intrinsic discount
Early Cancer Detection And MRD Leadership Will Deliver Outsized Long-Term Oncology Testing Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Early Cancer Detection And MRD Leadership Will Deliver Outsized Long-Term Oncology Testing Upside
Catalysts About Caris Life Sciences Caris Life Sciences is a precision medicine company that leverages Whole Exome, Whole Transcriptome and whole genome sequencing, cloud computing and AI to transform cancer diagnostics, treatment selection and prevention. What are the underlying business or industry changes driving this perspective?Read more
16
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$45
37.2% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
31.46% p.a.
Profit Margin
26.33%
Future PE
42.08x
Price in 2028
US$55.34
Trending Discussion
Recently Updated Narratives
AN
Early Cancer Detection And MRD Leadership Will Deliver Outsized Long-Term Oncology Testing Upside
Fair Value: US$45 37.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Caris Life Sciences, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -2.42
- 60.18%
- -105.05%
- 78.7%
About CAI
- Founded
- 2008
- Employees
- 1769
- CEO
- WebsiteView website
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company’s molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
